ArticleInfection2026
Role of ¹⁸F-FDG PET/CT in monitoring treatment response in extrapulmonary tuberculosis: a retrospective observational study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonitoring treatment response in tuberculosis (TB) remains a major clinical challenge, particularly in extrapulmonary forms. 18-F Fluorodeoxyglucose positron emission tomography (
methodsWe performed a retrospective observational study at a tertiary hospital in Spain, including adult patients diagnosed with extrapulmonary TB who underwent a baseline
resultsTwelve patients were included, most commonly with lymphatic (41.7%) or bone involvement (33.3%). At the end of the initially planned treatment, seven patients (58.3%) showed a marked (> 50%) reduction in SUVmax. Clinical outcomes were favourable in all seven. In contrast, the remaining five (41.7%) showed persistent or increased metabolic uptake. Among these, two had favourable clinical outcomes, suggesting sterile inflammation. The other three patients had an unfavourable clinical evolution with persistent symptoms. In two of them, new targeted biopsies demonstrated an alternative diagnosis.
conclusion
Indexed as
Identifiers
42848181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.